Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells

Experimental Cell Research

Volumn 328, Issue 2, 2014, Pages 351-360

  Wu, Juanjuan ^a   Williams, Devin ^b   Walter, Grant A ^a   Thompson, Winston E ^b   Sidell, Neil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen; Nrf2 activation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; PROTEIN KINASE B; SULFORAPHANE; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2; WORTMANNIN; ESTROGEN RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NFE2L2 PROTEIN, HUMAN;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HORMONAL REGULATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; ESTROGENS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HEME OXYGENASE-1; HUMANS; MCF-7 CELLS; NF-E2-RELATED FACTOR 2; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROGESTERONE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84908202950     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.08.030     Document Type: Article

References (63)

1. Nguyen T., Nioi P., Pickett C.B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 2009, 284:13291-13295. 10.1074/jbc.R900010200.
2. Venugopal R., Jaiswal A.K. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998, 17(24):3145-3156.
3. Lee J.M., Johnson J.A. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 2004, 37(2):139-143.
4. Jaiswal A.K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med. 2004, 36(10):1199-1207.
5. McWalter G.K., Higgins L.G., McLellan L.I., Henderson C.J., Song L., Thornalley P.J., Itoh K., Yamamoto M., Hayes J.D. Transcription factor Nrf2 is essential for induction of NAD(P)H: quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J. Nutr. 2004, 134(12 Suppl.):S3499S-S3506S.
6. Alam J., Stewart D., Touchard C., Boinapally S., Choi A.M., Cook J.L. Nrf2, a Cap 'n' Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 1999, 274(37):26071-26078.
7. Wild A.C., Moinova H.R., Mulcahy R.T. Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J. Biol. Chem. 1999, 274(47):33627-33636.
8. Yueh M.F., Tukey R.H. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. J. Biol. Chem. 2007, 282(12):8749-8758.
9. Kanematsu S., Yoshizawa K., Uehara N., Miki H., Sasaki T., Kuro M., Lai Y.C., Kimura A., Yuri T., Tsubura A. Sulforaphane inhibits the growth of KPL-1 human breast cancer cells in vitro and suppresses the growth and metastasis of orthotopically transplanted KPL-1 cells in female athymic mice. Oncol. Rep. 2011, 26(3):603-608. 10.3892/or.2011.1311.
10. Kim E.H., Deng C., Sporn M.B., Royce D.B., Risingsong R., Williams C.R., Liby K.T. CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prev. Res. 2012, 5(1):89-97. 10.1158/1940-6207.CAPR-11-0359.
11. Hayes J.D., McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 2009, 34(4):176-188. (Apr). 10.1016/j.tibs.2008.12.008.
12. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K.H., Yeo C.J., Calhoun E.S., Scrimieri F., Winter J.M., Hruban R.H., Iacobuzio-Donahue C., Kern S.E., Blair I.A., Tuveson D.A. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475(7354):106-109. (Jul 6). 10.1038/nature10189.
13. Kim S.K., Yang J.W., Kim M.R., Roh S.H., Kim H.G., Lee K.Y., Jeong H.G., Kang K.W. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic. Biol. Med. 2008, 45(4):537-546. (Aug 15). 10.1016/j.freeradbiomed.2008.05.011.
14. Zhong Y., Zhang F., Sun Z., Zhou W., Li Z.Y., You Q.D., Guo Q.L., Hu R. Drug resistance associates with activation of Nrf2 in MCF7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Mol. Carcinog. 2013, 52(10):824-834. (Oct). 10.1002/mc.21921.
15. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999, 13(1):76-86. (Jan 1).
16. Jain A.K., Jaiswal A.K. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J. Biol. Chem. 2007, 282(22):16502-16510. (Jun 1).
17. Niture S.K., Jain A.K., Shelton P.M., Jaiswal A.K. Src subfamily kinases regulate nuclear export and degradation of transcription factor Nrf2 to switch off Nrf2-mediated antioxidant activation of cytoprotective gene expression. J. Biol. Chem. 2011, 286(33):28821-28832. (Aug 19). 10.1074/jbc.M111.255042.
18. Chowdhry S., Zhang Y., McMahon M., Sutherland C., Cuadrado A., Hayes J.D. Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene. 2013 Aug 8;32(32):3765-3781. 10.1038/onc.2012.388.
19. Rada P., Rojo A.I., Chowdhry S., McMahon M., Hayes J.D., Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell. Biol. 2011, 31(6):1121-1133. (Mar). 10.1128/MCB.01204-10.
20. Rushmore T.H., Morton M.R., Pickett C.B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 1991, 266(18):11632-11639. (Jun 25).
21. Cullinan S.B., Zhang D., Hannink M., Arvisais E., Kaufman R.J., Diehl J.A. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell. Biol. 2003, 23(20):7198-7209. (Oct).
22. Liu J., Sidell N. Anti-estrogenic effects of conjugated linoleic acid through modulation of estrogen receptor phosphorylation. Breast Cancer Res. Treat. 2005, 94(2):161-169. (Nov).
23. Murphy A.A., Zhou M.H., Malkapuram S., Santanam N., Parthasarathy S., Sidell N. RU486-induced growth inhibition of human endometrial cells. Fertil. Steril. 2000, 74(5):1014-1019. (Nov).
24. Han S.W., Greene M.E., Pitts J., Wada R.K., Sidell N. Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin. Cancer Res. 2001, 7(1):98-104. (Jan).
25. Sidell N., Feng Y., Hao L., Wu J., Yu J., Kane M.A., Napoli J.L., Taylor R.N. Retinoic acid is a cofactor for translational regulation of vascular endothelial growth factor in human endometrial stromal cells. Mol. Endocrinol. 2010, 24(1):148-160. (Jan). 10.1210/me.2009-0155.
26. Sun J., Huang Y.R., Harrington W.R., Sheng S., Katzenellenbogen J.A., Katzenellenbogen B.S. Antagonists selective for estrogen receptor alpha. Endocrinology 2002, 143(3):941-947. (Mar).
27. Compton D.R., Sheng S., Carlson K.E., Rebacz N.A., Lee I.Y., Katzenellenbogen B.S., Katzenellenbogen J.A. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. J. Med. Chem. 2004, 47(24):5872-5893. (Nov 18).
28. Blommaart E.F., Krause U., Schellens J.P., Vreeling-Sindelárová H., Meijer A.J. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur. J. Biochem. 1997, 243(1-2):240-246. (Jan 15).
29. Tighe A., Ray-Sinha A., Staples O.D., Taylor S.S. GSK-3 inhibitors induce chromosome instability. BMC Cell Biol. 2007 Aug 14;8:34.
30. Donahue A.C., Kharas M.G., Fruman D.A. Measuring phosphorylated Akt and other phosphoinositide 3-kinase-regulated phosphoproteins in primary lymphocytes. Methods Enzymol. 2007, 434:131-154.
31. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995, 81(5):727-736. (Jun 2).
32. Das B.N., Kim Y.W., Keum Y.S. Mechanisms of Nrf2/Keap1-dependent phase II cytoprotective and detoxifying gene expression and potential cellular targets of chemopreventive isothiocyanates. Oxidative Med. Cell. Longev. 2013, 2013:839409. 10.1155/2013/839409.
33. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378(6559):785-789. (Dec 21-28).
34. Seng S., Avraham H.K., Jiang S., Yang S., Sekine M., Kimelman N., Li H., Avraham S. The nuclear matrix protein, NRP/B, enhances Nrf2-mediated oxidative stress responses in breast cancer cells. Cancer Res. 2007, 67(18):8596-8604. (Sep 15).
35. Nioi P., Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem. Biophys. Res. Commun. 2007, 362(4):816-821. (Nov 3).
36. Zembutsu H. Keap1-Nrf2 pathway and drug resistance in epithelial ovarian cancer. Pharmacogenomics 2011, 12(11):1516-1517. (Nov).
37. Ansell P.J., Lo S.C., Newton L.G., Espinosa-Nicholas C., Zhang D.D., Liu J.H., Hannink M., Lubahn D.B. Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha. Mol. Cell. Endocrinol. 2005, 243(1-2):27-34. (Nov 24).
38. Chen C.S., Tseng Y.T., Hsu Y.Y., Lo Y.C. Nrf2-Keap1 antioxidant defense and cell survival signaling are upregulated by 17β-estradiol in homocysteine-treated dopaminergic SH-SY5Y cells. Neuroendocrinology 2013, 97(3):232-241. 10.1159/000342692.
39. Gorrini C., Gang B.P., Bassi C., Wakeham A., Baniasadi S.P., Hao Z., Li W.Y., Cescon D.W., Li Y.T., Molyneux S., Penrod N., Lupien M., Schmidt E.E., Stambolic V., Gauthier M.L., Mak T.W. Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. Proc. Natl. Acad. Sci. USA 2014, 111(12):4472-4477. (Mar 25). 10.1073/pnas.1324136111.
40. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407(6803):538-541. (Sep 28).
41. Simoncini T., Rabkin E., Liao J.K. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23(2):198-203. (Feb 1).
42. Kinga P., Giulia P., Stefania S., Veronica I., Ida M., Tommaso S. Extra-nuclear estrogen receptors: effects on the cardiovascular system. Arch. Perinat. Med. 2012, 18(1):37-46.
43. Kandouz M., Siromachkova M., Jacob D., Chretien Marquet B., Therwath A., Gompel A. Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int. J. Cancer 1996, 68(1):120-125. (Sep 27).
44. Banerjee S., Saxena N., Sengupta K., Tawfik O., Mayo M.S., Banerjee S.K. WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 2003, 5(1):63-73. (Jan-Feb).
45. Poulin R., Dufour J.M., Labrie F. Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin. Breast Cancer Res. Treat. 1989, 13(3):265-276. (Jul).
46. Pawlak K.J., Wiebe J.P. Regulation of estrogen receptor (ER) levels in MCF7 cells by progesterone metabolites. J. Steroid Biochem. Mol. Biol. 2007, 107(3-5):172-179. (Nov-Dec).
47. Chen F.P., Chien M.H., Chen H.Y., Huang T.S., Ng Y.T. Effects of estradiol and progestogens on human breast cells: regulation of sex steroid receptors. Taiwan. J. Obstet. Gynecol. 2013, 52(3):365-373. (Sep). 10.1016/j.tjog.2012.09.038.
48. Berkenstam A., Glaumann H., Martin M., Gustafsson J.A., Norstedt G. Hormonal regulation of estrogen receptor messenger ribonucleic acid in T47Dco and MCF7 breast cancer cells. Mol. Endocrinol. 1989, 3(1):22-28. (Jan).
49. Savoldi G., Ferrari F., Ruggeri G., Sobek L., Albertini A., Di Lorenzo D. Progesterone agonists and antagonists induce down- and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines. Int. J. Biol. Markers 1995, 10(1):47-54. (Jan-Mar).
50. Gharavi N., Haggarty S., El-Kadi A.O. Chemoprotective and carcinogenic effects of tert-butylhydroquinone and its metabolites. Curr. Drug Metab. 2007, 8(1):1-7. (Jan).
51. Zhang D.D., Lo S.C., Cross J.V., Templeton D.J., Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 2004, 24(24):10941-10953. (Dec).
52. Kobayashi A., Kang M.I., Watai Y., Tong K.I., Shibata T., Uchida K., Yamamoto M. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell. Biol. 2006, 26(1):221-229. (Jan).
53. Yu J., Zhao Y., Li B., Sun L., Huo H. 17β-estradiol regulates the expression of antioxidant enzymes in myocardial cells by increasing Nrf2 translocation. J. Biochem. Mol. Toxicol. 2012, 26(7):264-269. (Jul). 10.1002/jbt.21417.
54. Gupta Vivek Kumar, Sharma Surendra Kumar Plants as natural antioxidants. Nat. Prod. Radiance 2006, 5(4):326-334.
55. Lau A., Whitman S.A., Jaramillo M.C., Zhang D.D. Arsenic-mediated activation of the Nrf2-Keap1 antioxidant pathway. J. Biochem. Mol. Toxicol. 2013, 27(2):99-105. (Feb). 10.1002/jbt.21463.
56. Solis L.M., Behrens C., Dong W., Suraokar M., Ozburn N.C., Moran C.A., Corvalan A.H., Biswal S., Swisher S.G., Bekele B.N., Minna J.D., Stewart D.J. Wistuba II. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin. Cancer Res. 2010, 16(14):3743-3753. (Jul 15). 10.1158/1078-0432.CCR-09-3352.
57. Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., Asamura H., Yamamoto M., Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. USA 2008, 105(36):13568-13573. (Sep 9). 10.1073/pnas.0806268105.
58. Shibata T., Kokubu A., Gotoh M., Ojima H., Ohta T., Yamamoto M., Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008, 135(4):1358-1368. (Oct), (1368.e1-4). 10.1053/j.gastro.2008.06.082.
59. Konstantinopoulos P.A., Spentzos D., Fountzilas E., Francoeur N., Sanisetty S., Grammatikos A.P., Hecht J.L., Cannistra S.A. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 2011, 71(15):5081-5089. (Aug 1). 10.1158/0008-5472.CAN-10-4668.
60. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314(5797):268-274. (Oct 13).
61. Yoo N.J., Kim H.R., Kim Y.R., An C.H., Lee S.H. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 2012, 60(6):943-952. (May). 10.1111/j.1365-2559.2012.04178.x.
62. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., Chen W., Yi X., Zheng W., Wondrak G.T., Wong P.K., Zhang D.D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008 Jun, 29(6):1235-1243. 10.1093/carcin/bgn095.
63. Chen Q., Li W., Wan Y., Xia X., Wu Q., Chen Y., Lai Z., Yu C., Li W. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology 2012, 55(6):1820-1829. (Jun). 10.1002/hep.25549.